# A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)

> **NCT01003431** · PHASE3 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Rotavirus Gastroenteritis
- Diphtheria
- Tetanus
- Pertussis

## Interventions

- **BIOLOGICAL:** Rotavirus Vaccine, Live, Oral, Pentavalent
- **BIOLOGICAL:** Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP)
- **BIOLOGICAL:** Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)

## Key facts

- **NCT ID:** NCT01003431
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-12
- **Primary completion:** 2010-08
- **Final completion:** 2010-09
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01003431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01003431, "A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01003431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*